15:26:46 EDT Mon 18 Oct 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Hemostemix Inc
Symbol HEM
Shares Issued 756,811,552
Close 2020-10-08 C$ 0.005
Recent Sedar Documents

ORIGINAL: Hemostemix wins motion to quash service re Aspire

2020-10-08 07:23 ET - News Release

Received by email:

File: '\\doc\emailin\20201008 032547 Attachment 2020 - 43 - News Release - Hemostemix Announces Win in Florida.docx'






CAN: 34494641.3



Hemostemix Announces Partial Win in Florida
Calgary, Alberta, October 8, 2020- Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV:HEM; OTC: HMTXF) is pleased t
--->o announce the Ninth Judicial Circuit Court for Orange County, Florida (the "Court") granted Hemostemix's motion to qu
--->ash service of process by Aspire Health Service, LLC ("Aspire") in Aspire's action filed against Hemostemix for declar
--->atory relief and specific performance in relation to the amended licensing agreement among Aspire and Hemostemix which
---> Hemostemix properly rescinded on December 5,   2019 . Aspire has 120 days to perfect service under the Hague Service 
--->Convention and file proof of service, failing which the complaint against Hemostemix will be dismissed without prejudi
--->ce. 
The Company's motion to dismiss Aspire's claims on jurisdictional and mandatory arbitration grounds was not granted. T
--->he Order is immediately appealable and on Friday October 2, 2020, Hemostemix filed both a notice of appeal of the Cour
--->t's order and a motion to stay the proceedings in the Florida action, pending the appeal. 

ABOUT HEMOSTEMIX 
Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology 
--->Pioneer Award, Hemostemix developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angi
--->na, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat ov
--->er 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and effic
--->acy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from ampu
--->tation. 
On October 21, 2019, Hemostemix announced the results from its Phase II CLI trial abstract entitled "Autologous Stem C
--->ell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Ye
--->ar Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outc
--->omes maintained for up to 4.5 years.  
Hemostemix owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with
---> Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, pleas
--->e visit www.hemostemix.com. 
Contact: Thomas Smeenk, President, CEO & Co-Founder
TSmeenk@Hemostemix.com   905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of th
--->e TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable
---> Canadian securities legislation. All statements, other than statements of historical fact, included herein are forwar
--->d-looking information. In particular, this news release contains forward-looking information  in relation to: the comm
--->ercialization of ACP-01. There can be no assurances that such forward-looking information will prove to be accurate, a
--->nd actual results and future events could differ materially from those anticipated in such forward-looking information
--->.  This forward-looking information reflects Hemostemix's current beliefs and is based on information currently availa
--->ble to Hemostemix and on assumptions which Hemostemix believes are reasonable. These assumptions include, but are not 
--->limited to: the underlying value of Hemostemix and its common shares; the successful resolution of the litigation that
---> Hemostemix is pursuing or defending (the "Litigation"); the timing of receipt of its full and complete clinical trial
--->s data; the results of ACP-01 research, trials and studies being equivalent to or better than previous research, trial
--->s or studies as well as management's expectations of anticipated results; Hemostemix's general and administrative cost
--->s remaining constant; the receipt of all required regulatory approvals for research, trials or studies as well as any 
--->required or desired financings of Hemostemix , including TSX Venture Exchange acceptance and any third party consents;
---> the level of activity, market acceptance and market trends in the healthcare sector; the  economy generally; consumer
---> interest in Hemostemix's services and products; competition and  Hemostemix's competitive advantages; and obtaining s
--->atisfactory financing to fund Hemostemix's operations including any research, trials or studies and the Litigation. Fo
--->rward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the ac
--->tual results, level of activity, performance or achievements of Hemostemix to be materially different from those expre
--->ssed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to:
---> the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory futility analysis and t
--->he results of such and future clinical trials; litigation and potential litigation that Hemostemix may face; general b
--->usiness, economic, competitive, political and social uncertainties; general capital market conditions and market price
--->s for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations i
--->ncluding the actual results of future research, trials or studies; competition; changes  in legislation affecting Hemo
--->stemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and futu
--->re developments in the Company's markets and the markets in which it expects to compete;  lack of qualified, skilled l
--->abour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders
---> and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures
--->, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social dis
--->tancing, disruptions to: markets, economic activity, financings, supply chains and sales channels, and a deterioration
---> of general economic conditions including a possible national or global recession or depression; the potential impact 
--->that the COVID-19 pandemic may have on Hemostemix may include a decreased demand for the services that Hemostemix offe
--->rs; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A des
--->cription of additional risk factors that may cause actual results to differ materially from forward-looking informatio
--->n  can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has at
--->tempted to identify important factors that could cause actual results to differ materially from those contained in for
--->ward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intende
--->d. Readers are cautioned that the foregoing list of factors is not exhaustive.  Readers are further cautioned not to p
--->lace undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectat
--->ions upon which they are placed will occur. Forward-looking information contained in this news release is expressly qu
--->alified by this cautionary statement. The forward-looking information contained in this news release represents the ex
--->pectations of Hemostemix as of the date  of this news release and, accordingly, it is subject to change after such dat
--->e. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking informa
--->tion, whether as a result of new information, future events or otherwise, except as expressly required by applicable s
--->ecurities law. 




© 2021 Canjex Publishing Ltd. All rights reserved.